中国临床药理学杂志Issue(15)：1494-1496,3.DOI:10.13699/j.cnki.1001-6821.2015.15.008
康莱特联合吉西他滨、顺铂治疗晚期非小细胞肺癌的临床疗效及安全性评价
Clinical efficacy and safety of Kanglaite combined with gemcitabine and cisplatinum chemotherapy in the treatment of advanced non-small cell lung cancer
摘要
Abstract
Objective To evaluate the clinical efficacy, safety and affection for T lymph cell subgroup by gemcitabine and cisplatinum chemotherapy combined with Kanglait in the treatment of advanced non-small cell lung carcinoma.Methods Sixty -nine non -small lung cancer patients were included in this study and randomly divided into control group ( n=36 ) and treatment group ( n=33 ).The patients in the control group were treated with gemcitabine 1000 mg · m-2 , day 1, 8 +cisplatinum 80 mg· m-2 , day 2, three weeks per cycle with 2 cycles treatment.Patients in the treatment group were treated with basis on control group, plus Kanglaite injection 200 mL qd ×10 days per cycle for 2 cycles with the chemotherapy regimen.After 2 cycles chemotherapy treatment, the clinical efficacy, chemotherapy related toxicity and T lymph cell subgroup were analyzed between the two groups.Results The objective response rate were 22.22%and 27.27%for the control and treatment group respectively without statistical difference ( P>0.05).The T lymph cell subgroup in treatment group was signifi-cant higher than in the control group ( P <0.05 ) .The main chemotherapy related toxicity were bone marrow depression and gastrointestinal reaction with no statistical difference between the two groups ( P>0.05).Conclusion Gemcitabine+cisplatinum chemotherapy combined with Kanglait can elevate the T lymph cell subgroup and decrease the chemotherapy toxicity.关键词
康莱特/非小细胞肺癌/吉西他滨/顺铂/临床疗效Key words
Kanglaite/non-small cell lung cancer/gemcitabine/cisplatinum/clinical efficacy分类
医药卫生引用本文复制引用
姚德蛟..康莱特联合吉西他滨、顺铂治疗晚期非小细胞肺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,(15):1494-1496,3.基金项目
四川省中医药管理局基金资助项目 （）
